We wanted to compare cancer incidence rates between Parkinson's disease (PD) patients and persons without PD, as well as between siblings of these groups. We conducted a family-based matched cohort study based on nationwide Swedish health registries and the Swedish Multi-Generation Register. We assessed risk of incident cancer in PD patients (n = 11,786) during 1964-2009 versus a matched cohort of PD-free individuals (n = 58,930) and in siblings of PD patients (n = 16,841) versus siblings of PD-free individuals (n = 84,205). Hazard ratios with 95% confidence intervals were estimated using Cox proportional hazards regression. Cancer occurrence was slightly higher in PD patients than in PD-free individuals (hazard ratio (HR) = 1.05, 95% confidence interval (CI): 1.00, 1.10), largely because of cancers arising within 1 year before or after the index date for PD, but risk of smokingrelated cancers was lower (HR = 0.87, 95% CI: 0.79, 0.96). PD patients had a higher risk of melanoma both up to 1 year before the PD index date (HR = 1.53, 95% CI: 1.23, 1.91) and from 1 year after the index date onward (HR = 1.46, 95% CI: 1.01, 2.10). In the sibling comparison, cancer occurrence was largely similar. These results indicate that melanoma risk is higher among PD patients and that mechanisms other than familial ones explain the association.
Growing epidemiologic evidence suggests a lower risk of cancer, specifically smoking-related cancer, among Parkinson's disease (PD) patients (1, 2) . In contrast, melanoma risk seems to be higher among PD patients (3) . Little is known about the reasons for these associations. Noncausal explanations, such as confounding by smoking, by survival, and by ascertainment biases, have been suggested. Another suggested explanation is common genetic susceptibility, particularly for melanoma (4, 5) . We wanted to address some of these controversies by taking advantage of Sweden's national health registers.
Our aims in the present study were 1) to analyze the association between PD and cancer and their temporal relationships and 2) to assess whether shared familial factors may explain a possible association. We used a matched cohort sibling design, comparing cancer occurrence in a cohort of PD patients with that in a matched general-population cohort free of PD, as well as between siblings of persons in these 2 cohorts. In the PD-patient versus PD-free cohort comparison, we considered 3 different time windows for incident cancer: up to 1 year prior to the index date for PD, from 1 year before the PD index date to 1 year after the index date, and from 1 year after the PD index date onward. We chose the time period in close proximity to the PD index date in order to examine the presence of ascertainment bias.
MATERIALS AND METHODS

Study population
residents of Sweden born since 1932 who were alive and living in Sweden after 1961 (6) . The study population included persons in the Multi-Generation Register who were born between January 1, 1932, and December 31, 1991. Because the Swedish Cancer Register was started in 1958, persons who immigrated to Sweden as adults (age ≥18 years) after December 31, 1957, were excluded (since cancers diagnosed prior to immigration may have been missed). After this exclusion, the study population included 6,757,842 persons.
Swedish Patient Register
PD cases were identified from the Swedish Patient Register (http://www.socialstyrelsen.se/english). The Inpatient Register, which was started in 1964 and achieved full nationwide coverage in 1987, includes information on hospital discharge diagnoses coded according to the International Classification of Diseases, Seventh Revision (ICD-7) (7) 
Identification of PD patients
To identify PD patients, we used codes 350, 342, 332.0, and G20 from the Seventh, Eighth, Ninth, and Tenth revisions of the International Classification of Diseases, respectively. Both primary and secondary diagnoses were considered. We used the date of first hospital discharge or outpatient contact as the index date. PD diagnoses from the Inpatient Register were previously validated against clinical examinations in the Swedish Twin Register and showed a positive predictive value of 70.8% and a sensitivity of 72.7% for any register PD diagnosis ( primary or secondary) (8) . The Outpatient Register PD diagnoses have not been validated.
PD patients versus PD-free individuals
For the period 1964-2009, we identified 11,820 persons with incident PD in the study population. We excluded 34 PD patients because they had an index date for PD before age 20 years (indicating a coding error). For each of the remaining 11,786 PD patients, we randomly selected 5 persons who were free of PD during the entire follow-up period, were alive, and were still under follow-up on the PD patient's index date, matched by birth year and sex (n = 58,930). Thus, in total, 70,716 persons were included in the analysis of PD patients versus PD-free individuals (Figure 1) .
Siblings of PD patients versus siblings of PD-free individuals
In the study population of 6,757,842 persons, we identified 5,311,104 individuals, designated "index persons," who had siblings (7,340 PD patients and 5,303,764 PD-free individuals). To account for the different numbers of siblings in families, the selection of siblings was based on pairwise combinations of siblings rather than on complete families. Thus, among the 5,311,104 index persons, we considered all 11,427,726 possible pairwise combinations of siblings (sibling pairs). For example, in a family with 3 children, there were 3 possible pairwise combinations (siblings 1 and 2, siblings 1 and 3, and siblings 2 and 3), and each sibling was represented in 2 possible combinations. Overall, we identified 16,923 sibling pairs with a PD patient as the index person (including sibling pairs in which both siblings had PD) and 11,410,803 sibling pairs with a PD-free individual as the index person (including sibling pairs with a PD-free individual as the index person and a PD patient as a sibling). Among the latter, we randomly selected 5 sibling pairs for each sibling pair in which the index person had PD (n = 84,582 pairs), matched on birth year and sex (for both individuals in the pair) and sibship (full sibling or half sibling). The index person of the selected pairs was required to be alive and living in Sweden on the PD patient's index date. Among the 101,505 (16,923 + 84,582) sibling pairs, we excluded 414 pairs because they had an index date before age 20 years and 45 pairs because fewer than 5 matching sibling pairs were identified. Among the remaining 101,046 sibling pairs, 16,841 siblings of PD patients and 84,205 siblings of PD-free individuals were included in the analyses (Figure 1 ). The 16,841 individuals were siblings of 7,308 unique PD patients.
Cancer Register
Cancer diagnoses were identified from the nationwide Swedish Cancer Register, which was started in 1958 and includes cancer diagnoses (ICD-7 codes 140-204) from both clinicians and pathologists (http://www.socialstyrelsen. se/english). The overall completeness of the Cancer Register is high (9) . Using ICD-7 codes, we grouped cancer sites according to their relation to smoking. Smoking-related cancers included oral cancers and cancers of the esophagus, stomach, liver, pancreas, nose and nasal sinuses, larynx, trachea, bronchus, lung, pleura, cervix uteri, kidney, and urinary organs. Non-smokingrelated cancers included cancers of the small intestine, peritoneum, mediastinum, breast, prostate, testis, bone, connective tissue, and muscle; endocrine cancers; malignant melanoma of the skin; and skin cancers other than melanoma. Cancers with an unknown association with smoking included cancers of the nervous system, colon, rectum, anus, corpus uteri, ovary, male genital organs other than the prostate and testis, and the thyroid gland; lymphoma; multiple myeloma; lymphatic leukemia; and unspecified cancers. Information from the Cancer Register was available for the period 1958-2009. In the case of multiple cancers, only the first primary cancer diagnosis was considered, and the date of diagnosis was defined as the date of first entry in the Cancer Register.
Education Register
Statistical analysis
In the comparison of PD patients with PD-free individuals, we analyzed incident cancer during the entire follow-up period from January 1, 1958 the index date for PD; from 1 year before the PD index date to 1 year after the index date; and from 1 year after the PD index date to December 31, 2009 ( Figure 2 ). In the comparison of siblings of PD patients with siblings of PD-free individuals, we analyzed incident cancer that occurred from January 1, 1958, to December 31, 2009. Considering the entire followup period as well as each time window separately, study subjects were followed from the start of follow-up to the first diagnosis of any cancer, death (from the Cause-of-Death Register), migration out of Sweden (data were available until 2002), or the end of follow-up. Persons younger than age 18 years in 1958 were followed from the date on which they turned 18.
Hazard ratios with 95% confidence intervals were estimated using Cox proportional hazards regression models with attained age as the time scale. The models were stratified on the matching variables and adjusted for education. Hazard ratios were not calculated for cancer sites with fewer than 5 cases in any of the compared groups. The assumption of proportional hazards was evaluated using Schoenfeld residuals. For cancer sites for which the assumption was violated, we also examined the hazards graphically and found that hazards were unproportional mainly among young study participants, who had low incidence rates. We performed analyses for cancer overall, for cancer type according to relationship with smoking, and for specific cancer sites. To assess whether sex could be an effect modifier, we included an interaction term for sex in the model. For PD patients versus PD-free individuals, we performed analyses stratified by PD index date (age <65 years, age ≥65 years). We also performed sensitivity analyses, restricting the definition of PD to the primary diagnosis in the Patient Register and to cases with a first Outpatient Register diagnosis between 2003 and 2009. We performed the latter analysis to reduce the impact of potential bias related to prevalent cases, assuming that disease duration is shorter for outpatient PD diagnoses than for inpatient diagnoses and that cases identified during the first 2 years of the Outpatient Register's existence were more likely to be prevalent. Stata software (10) was used for the statistical analyses. The study protocol was approved by the Regional Ethics Committee in Stockholm.
RESULTS
Of the 11,786 PD patients, 7,135 (60.5%) were men, and the mean age at the PD index date was 62.5 (standard deviation (SD), 9.2) years. Over two-thirds of patients (n = 8,067; 68.5%) were identified from the Outpatient Register.
Compared with PD patients, proportionally, there were fewer men among siblings of PD patients ( Table 1) . Siblings of PD patients were younger than PD patients, on average. Educational level was similar in PD patients, PD-free individuals, and siblings. Mean age at the end of follow-up was 66.2 (SD, 9.8) years for PD patients and PD-free individuals and 60.8 (SD, 11.5) years for siblings of PD patients and siblings of PD-free individuals.
Among the 11,782 PD patients for whom results are shown in Table 2 , a total of 2,196 (18.6%) received a cancer diagnosis during follow-up, and among the 58,919 PD-free individuals, there were 10,991 (18.7%) cancer cases. The most common cancer sites were the prostate in men and the cervix uteri, followed by the breast, in women. The mean age at cancer diagnosis was 59.5 (SD, 12.1) years for PD patients and 59.9 (SD, 12.8) years for PD-free individuals.
Considering the entire follow-up period, there was a marginally increased risk of cancer at all sites in PD patients versus PD-free individuals (hazard ratio (HR) = 1.05, 95% confidence interval (CI): 1.00, 1.10), with a slightly increased risk for non-smoking-related cancers (HR = 1.10, 95% CI: During the period up to 1 year prior to the PD index date, PD patients had increased risk of non-smoking-related cancer in comparison with PD-free individuals but marginally lower risk of smoking-related cancer (Table 2 ). Higher risks of melanoma, endocrine cancer, and corpus uteri cancer and lower risks of oral and cervix uteri cancers were observed among PD patients. The risks did not differ statistically for any other cancer site. During the period from 1 year before the PD index date to 1 year after the index date, PD patients had a higher cancer risk overall and generally by site (Table 2 ). In the analyses of cancer risk at least 1 year after the PD index date, PD patients had an overall lower risk for cancer, largely due to smoking-related cancer. The risks of non-smoking-related cancer were similar in PD patients and PD-free individuals; however, a higher risk of melanoma and other skin cancer and a lower risk of prostate cancer were observed in PD patients ( Table 2 ). The results were largely similar in men and women and in PD patients with index dates before and after age 65 years (data not shown).
When we restricted the analyses to primary PD diagnoses, there was no significant risk increase for non-smoking-related cancer until 1 year prior to the PD index date and no significant risk decrease for overall cancer from 1 year after the index date onward, as in the main analyses, but the results were largely similar for smoking-related cancer. For melanoma, there was a higher risk until 1 year prior to the PD index date, as in the main analyses, but for the periods 1 year before the PD index date to 1 year after the index date and 1 year after the index date onward, risk estimates did not reach statistical significance (data not shown). When analyses were restricted to outpatient PD diagnoses made between 2003 and 2009, there were generally no increased cancer risks from 1 year before the PD index date to 1 year after the index date, as in the main analyses. For the period up to 1 year prior to the PD index date and the period 1 year after the index date onward, risk estimates for overall cancer, smoking-related cancer, non-smoking-related cancer, and melanoma were largely similar to those from the main analyses, but several estimates did not reach statistical significance (data not shown).
During follow-up, 2,835 (16.9%) cancer cases were diagnosed among siblings of PD patients, and 14,314 (17.1%) were diagnosed among siblings of PD-free individuals ( Table 3 ). The overall cancer risks did not differ between these 2 groups, although among siblings of PD patients a lower risk was observed for pancreas cancer and a higher risk for prostate cancer and multiple myeloma. The risks of melanoma and other skin cancer were similar in siblings of PD patients and siblings of PD-free individuals.
DISCUSSION
In this large population-based register study, we found a modestly increased cancer risk among PD patients, due largely to higher risk during the period in proximity to the Parkinson's Disease and Cancer 89 Abbreviations: CI, confidence interval; HR, hazard ratio; ICD-7, International Classification of Diseases, Seventh Revision; PD, Parkinson's disease. a Time periods: up to 1 year prior to the index date for PD, from 1 year before the PD index date to 1 year after the index date, and 1 year after the PD index date onward. b Four of the 11,786 PD patients and 11 of the 58,930 PD-free individuals were excluded because they died, emigrated, or had an incident cancer diagnosed before the start of follow-up. Thus, results were tabulated for 11,782 PD patients and 58,919 matched cohort individuals. An additional 2,207 persons were excluded from the regression model because of missing information on educational level. In total, 68,494 persons were included in the analyses. c A total of 1,298 of the 11,786 PD patients and 5,914 of the 58,930 matched cohort individuals were excluded because they died, emigrated, or had an incident cancer diagnosed before the start of follow-up. Thus, results were tabulated for 10,488 PD patients and 53,016 matched cohort individuals. An additional 2,069 persons were excluded from the regression model because of missing information on educational level. In total, 61,435 persons were included in the analyses. d A total of 2,965 of the 11,786 PD patients and 13,031 of the 58,930 matched cohort individuals were excluded because they died, emigrated, or had an incident cancer diagnosed before the start of follow-up. Thus, results were tabulated for 8,821 PD patients and 45,899 matched cohort individuals. An additional 1,775 persons were excluded from the regression model because of missing information on educational level. In total, 52,945 persons were included in the analyses.
e HRs were estimated from a Cox proportional hazards regression model stratified by matched risk set and adjusted for educational level. The time scale was attained age. HRs are not presented for cancers with fewer than 5 cases. PD index date. However, risk of smoking-related cancers was lower among PD patients, most prominently after the PD index date. Of all types of cancer, melanoma was the only type for which the risk was consistently higher in all time periods. Overall, cancer risks were similar in siblings of PD patients and siblings of PD-free individuals, including risk of melanoma.
Emerging epidemiologic evidence suggests links between PD and cancer, especially lower risk of smoking-related cancer and higher risk of melanoma (1-3) . The potential association with melanoma is particularly interesting, since dopamine and melanin share biochemical pathways (L-3,4-dihydroxyphenylalanine (L-DOPA) is a precursor for both dopamine and melanin) (11) and neurons and melanocytes both have an embryonic origin from the neural crest (12) . In this context, it is also notable that we observed a higher risk of endocrine cancer up to 1 year prior to the PD index date, including pheocromocytoma and pituitary gland tumors, tissues which also share an embryonic origin with neurons. However, in the analysis of PD and cancer, ascertainment bias due to increased medical surveillance and survival bias could not be excluded. Because both PD and cancer are relatively rare diseases, previous studies often had small sample sizes and were unable to examine various possibilities.
Compared with most previous studies, our study was much larger, with nationwide data, allowing us to conduct analyses of temporal relationships to examine ascertainment bias and sibling analyses to explore whether genetic or shared familial exposures could explain observed associations. Further, the prospective design controlled for survival and censoring, and the use of the national cancer register permitted complete, independent, and unbiased assessment of cancer occurrence.
The temporal relationship analyses did suggest some degree of ascertainment bias for almost all cancer sites; the risk was particularly elevated around the time of the PD index date. Patients with a chronic disease tend to receive more medical attention than the general population. However, risk of melanoma was consistently higher during all time periods, suggesting that ascertainment bias is an unlikely explanation for this association. Our observation on melanoma is also consistent with a recent meta-analysis (3). Some case reports have suggested that L-DOPA treatment may increase the risk of melanoma (11) , but this explanation is unlikely, since in the present study as well as in the meta-analysis (3), melanoma risk was higher even prior to PD diagnosis.
A shared genetic mechanism has been proposed based on findings of increased PD risk among persons with lighter hair color (13) and a family history of melanoma (14) . Further, in a genealogical study, Kareus et al. (15) reported an excess risk of melanoma in PD patients and their relatives. Siblings share a part of the genome and early-life environment. Thus, if the association between PD and melanoma were primarily explained by these factors, with this sample size, we would expect to observe a robust, albeit small, difference in cancer incidence between siblings of PD patients and siblings of PDfree individuals. In support of our results, a study that examined PD risk in first-degree relatives of early-onset melanoma patients found no increased risk (16) . Similarly, another study that examined single-nucleotide polymorphisms selected from genome-wide association studies of PD in melanoma cases and controls found no associations (17) .
Our finding of a lower occurrence of smoking-related cancers in PD patients after the PD index date is in line with previous studies (2) , although the strength of this association was somewhat weaker than the associations in a meta-analysis (2) and a recent Danish study (18) . Possible explanations are differences in smoking behavior between populations and lack of control for survival in previous case-control studies. The possibility of bias could not be excluded, since our analysis showed a higher occurrence of these cancers around the time of the PD index date, which may explain the lower occurrence after the index date. An alternative possibility is that smoking in itself contributes to this observation, since smoking is associated with a substantially reduced risk of PD. Because there is no information on smoking in Sweden's nationwide registers, we were unable to evaluate this possibility. Other studies have observed that the lower occurrence of cancer in PD patients was not apparent when cancers diagnosed before the PD index date were considered (19, 20) , and this may be explained by duration of smoking (or nonsmoking; the longer the duration of nonsmoking, the lower the risk of smoking-related cancer).
As in any register-based study, our study had several limitations. Completeness of the Swedish Cancer Register is high, but the identification of PD cases from patient registers probably resulted in some degree of misdiagnosis and underdiagnosis, although our previous validation study (8) showed reasonable diagnostic accuracy and sensitivity of the Inpatient Register. We did not validate outpatient diagnoses; however, because these diagnoses are assigned by specialists, it is reasonable to assume that they are at least as accurate as inpatient diagnoses. It is difficult to predict exactly how misdiagnosis might affect the results, but most likely, risk estimates would be attenuated. Underdiagnosis may also have led to attenuation of the estimates; however, because PD is relatively rare, the underdiagnosis effect would most likely have been small. The identification of PD cases from registers also resulted in uncertainty about true age at PD onset, leading to uncertainties when defining the time windows. Because the true onset of PD probably occurs earlier than the first register diagnosis, this uncertainty affected our analyses of the time period up to 1 year prior to the PD index date and the time period from 1 year before the PD index date to 1 year after the index date. Further, some of our cases were probably prevalent cases, especially those identified during the first years after the inpatient and outpatient registers were started. However, our sensitivity analysis restricted to outpatient cases identified in 2003 or later showed results similar to those from the main analyses, although less marked increased risk for cancer close to the PD index date (likely reflecting less ascertainment bias due to shorter follow-up for PD). Our stratified analyses comparing cancer risk in early-onset PD versus late-onset PD showed similar results, but since age at onset is uncertain, this finding should be interpreted with caution. Because we had no information on confounders such as smoking, we were unable to control for these variables. Finally, because the Swedish Multi-Generation Register is based on persons born after 1931, attained age at the end of follow-up was relatively low. It is unlikely that this led to biased results, but longer follow-up would have improved statistical precision.
In conclusion, we showed an increased occurrence of melanoma among PD patients, which may be due to mechanisms other than shared familial factors. Increased medical attention with regard to melanoma should be considered for PD patients.
